Decnupaz Approved for Rare Blood Cancer

(MedPage Today) -- The FDA approved the antibody-drug conjugate pivekimab sunirine (Decnupaz) for the rare hematologic malignancy blastic plasmacytoid dendritic cell neoplasm (BPDCN). The approval stipulates use of the drug in adults. Although...
Source
MedPage Today
Opens original article in a new tab



